STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

News
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) announced the discontinuation of the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer patients. The trial was discontinued due to futility, as it was unlikely to meet its primary endpoints. The safety profile was consistent with previous studies, and investigation for other tumor types will continue. This does not impact the currently approved indication for patients with unresectable or metastatic melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
Rhea-AI Summary
Bristol Myers Squibb (BMY) will release its Q4 2023 results on February 2, 2024, with a conference call for investors and analysts at 8:00 a.m. ET. The live webcast can be accessed at http://investor.bms.com, and materials will be available prior to the call. A replay will also be available on the same website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences earnings
-
News
Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb
Rhea-AI Summary
Terray Therapeutics (BMY) collaborates with Bristol Myers Squibb to discover and develop small molecule therapeutics against certain disease areas. The collaboration includes upfront payment, milestone payments, and royalties on global net sales of products. Terray will utilize its tNova drug discovery platform to identify small molecule compounds against targets nominated by Bristol Myers Squibb, with Bristol Myers Squibb assuming responsibility for development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
News
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
Rhea-AI Summary
Bristol Myers Squibb (BMY) announced the results of two early studies evaluating combinations of golcadomide with R-CHOP and rituximab in non-Hodgkin lymphomas at the 2023 American Society of Hematology (ASH) Annual Meeting. The studies showed promising activity and combinability of golcadomide in patients with previously untreated aggressive B-cell lymphoma and heavily pretreated patients with diffuse large B-cell lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
News
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
Rhea-AI Summary
Bristol Myers Squibb (NYSE: BMY) presents updated results from multiple myeloma research pipeline at ASH, demonstrating deepening responses and durable outcomes for BMS-986393, mezigdomide, and alnuctamab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
News
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Rhea-AI Summary
Bristol Myers Squibb (BMY) and 2seventy bio, Inc. (TSVT) announced results from the final progression-free survival (PFS) analysis of KarMMa-3, a Phase 3 study evaluating Abecma in adults with relapsed and refractory multiple myeloma. Abecma maintained a 51% reduction in risk of disease progression or death with a median PFS of 13.8 months compared to 4.4 months for standard regimens. The complete response rate was 44% vs. 5% for standard regimens. Abecma demonstrated deep and durable responses in newly-diagnosed multiple myeloma with a 77% complete response rate and no new safety signals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
News
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
Rhea-AI Summary
SystImmune (BL-B01D1) and Bristol Myers Squibb (BMY) have entered into an exclusive license and collaboration agreement for the development and commercialization of BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate. The companies will jointly develop and commercialize BL-B01D1 in the United States, with SystImmune retaining exclusive rights in Mainland China and Bristol Myers Squibb gaining an exclusive license in the rest of the world. The financial highlights of the agreement include an $800 million upfront payment to SystImmune and up to $7.1 billion in contingent payments based on certain milestones, making the total potential consideration up to $8.4 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
News
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
Rhea-AI Summary
Bristol Myers Squibb (BMY) announced the primary analysis results from TRANSCEND FL, where 95.7% of patients with high-risk relapsed or refractory follicular lymphoma (FL) treated with Breyanzi achieved a complete response, with a manageable safety profile. Additionally, long-term follow-up data from TRANSCEND CLL 004 continue to demonstrate deep and durable complete responses and a manageable and predictable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
News
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
Rhea-AI Summary
Bristol Myers Squibb (BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS). Reblozyl demonstrated superior efficacy and durability compared to ESAs and is under review with the European Commission, with priority review approval by the United States Food and Drug Administration for the treatment of anemia in ESA-naïve adult patients with very low- to intermediate-risk MDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
Rhea-AI Summary
Bristol Myers Squibb (BMY) announced positive results from the Phase 3 CheckMate -8HW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in patients with MSI-H/dMMR metastatic colorectal cancer. The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, meeting the primary endpoint. The safety profile was manageable with no new safety signals identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
clinical trial
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#118 Ranked by Market Cap
#4058 Ranked by Stock Gains
#659 Ranked by Dividends

BMY Stock Data

97.81B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.